

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

Pan-TEAD (D3F7L) Rabbit mAb

RRID:AB_2687902

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 13295, RRID:AB_2687902

Antibody Information

URL: http://antibodyregistry.org/AB_2687902

Proper Citation: Cell Signaling Technology Cat# 13295, RRID:AB_2687902

Target Antigen: Pan-TEAD

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: Pan-TEAD (D3F7L) Rabbit mAb

Description: This monoclonal targets Pan-TEAD

Target Organism: Human, Rat, Monkey, Mouse

Clone ID: D3F7L

Antibody ID: AB_2687902

Vendor: Cell Signaling Technology

Catalog Number: 13295

Alternative Catalog Numbers: 13295S

Record Creation Time: 20231110T034040+0000

Record Last Update: 20260829T235352+0000

Ratings and Alerts

No rating or validation information has been found for Pan-TEAD (D3F7L) Rabbit mAb.

No alerts have been found for Pan-TEAD (D3F7L) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Doldi V, et al. (2026) FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target. *Journal of translational medicine*, 24(1).

Rominger MC, et al. (2025) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. *Cell reports*, 44(10), 116185.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. *Molecular cell*.

Lv J, et al. (2025) Mechanical signaling via $\alpha 2$ integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells. *Immunity*, 58(9), 2289.

Purdy SC, et al. (2025) eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small molecules. *Cell reports*, 44(12), 116643.

Nguyen CDK, et al. (2024) PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. *Cell reports*, 43(5), 114176.

Zhao Y, et al. (2024) Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis. *Nature communications*, 15(1), 2384.

Wang X, et al. (2024) Nuclear receptor E75/NR1D2 promotes tumor malignant transformation by integrating Hippo and Notch pathways. *The EMBO journal*, 43(24), 6336.

Lin LL, et al. (2024) PAI-1 uncouples integrin- $\beta 1$ from restrain by membrane-bound β -catenin to promote collagen fibril remodeling in obesity-related neoplasms. *Cell reports*, 43(8), 114527.

Noritsugu K, et al. (2023) Lysine long-chain fatty acylation regulates the TEAD transcription factor. *Cell reports*, 42(4), 112388.

Vaidyanathan S, et al. (2022) YAP regulates an SGK1/mTORC1/SREBP-dependent lipogenic program to support proliferation and tissue growth. *Developmental cell*, 57(6), 719.

Park S, et al. (2022) Transcription factors TEAD2 and E2A globally repress acetyl-CoA synthesis to promote tumorigenesis. *Molecular cell*, 82(22), 4246.

Fan S, et al. (2022) JAM-A signals through the Hippo pathway to regulate intestinal epithelial proliferation. *iScience*, 25(5), 104316.

Chang CY, et al. (2021) Increased ACTL6A occupancy within mSWI/SNF chromatin remodelers drives human squamous cell carcinoma. *Molecular cell*, 81(24), 4964.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Vigneswaran K, et al. (2021) YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(5), 1553.

Kurppa KJ, et al. (2020) Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. *Cancer cell*, 37(1), 104.

Shim J, et al. (2020) YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma. *Cancer research*, 80(21), 4741.